Year: 2022

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to

Recent

Phone
415.765.6980

Address

360 Post Street
Suite 601
San Francisco, CA 94108

Copyright 2022 Telegraph Hill Partners | All Rights Reserved | Powered by MITO